Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species

Medical Mycology

Volumn 50, Issue 6, 2012, Pages 658-660

  Warren, Thomas A ^a   Yau, Yvonne ^b   Ratjen, Felix ^b   Tullis, Elizabeth ^c   Waters, Valerie ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Aspergillus; Cystic fibrosis; Galactomannan

Indexed keywords

ANTIFUNGAL AGENT; GALACTOMANNAN; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CHILD; CYSTIC FIBROSIS; ENZYME IMMUNOASSAY; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SERUM; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FORCED EXPIRATORY VOLUME; OPTICAL DENSITY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; MALE; MANNANS; MIDDLE AGED; YOUNG ADULT;

ASPERGILLUS;

EID: 84863930039     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.676739     Document Type: Article

References (14)

1. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8: 386-391.
2. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 1979; 120: 863-873.
3. Pihet M, Carrere J, Cimon B, e t al . Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - a review. Med Mycol 2009; 47: 387-397.
4. Valenza G, Tappe D, Turnwald D, et al . Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7: 123-127.
5. Stevens DA, Moss RB, Kurup VP, e t al . Allergic bronchopulmonary aspergillosis in cystic fibrosis-State of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (Suppl. 3): S225-S264.
6. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137: 171-176.
7. Massam J, Bitnun A, Solomon M, e t al . Invasive aspergillosis in cystic fibrosis: A fatal case in an adolescent and review of the literature. Pediatr Infect Dis J 2011; 30: 178-180.
8. Sch ø nheyder H, Jensen T, Hø iby N, Andersen P, Koch C. Frequency of Aspergillus fumigatus isolates and antibodies to Aspergillus antigens in cystic fibrosis. Acta Pathol Microbiol Immunol Scand B 1985; 93: 105-112.
9. Waters V, Yau Y, Prasad S, e t al . Stenotrophomonas maltophilia in cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 635-640.
10. Walsh TJ, Shoham S, Petraitiene R, et al . Detection of galactomannan antigenemia in patients receiving piperacillin-Tazobactam and correlations between in vitro , in vivo , and clinical properties of the drugantigen interaction. J Clin Microbiol 2004; 42: 4744-4748.
11. Delhaes L, Frealle E, Pinel C. Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: State of the art and further challenges. Med Mycol 2010; 48 (Suppl. 1): S77-S87.
12. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999; 103: 303-307.
13. Hope WW, Kruhlak MJ, Lyman CA, et al . Pathogenesis of A spergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy. J Infect Dis 2007; 195: 455-466.
14. Hope WW, Petraitis V, Petraitiene R, et al . The initial 96 hours of invasive pulmonary aspergillosis: Histopathology, comparative kinetics of galactomannan and (1-3) D-Glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 2010; 54: 4879-4886.